Epidermal growth factor vaccine in non-small-cell lung cancer

Expert Review of Anticancer Therapy

Volumn 12, Issue 4, 2012, Pages 439-445

  Gonzalez Marinello, Gisela M ^a   Santos, Edgardo S ^b   Raez, Luis E ^c  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b UNIVERSITY OF MIAMI   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

belagenpumetucel L; BLP 25; CIMAvax EGF; epidermal growth factor; immunotherapy; melanoma associated antigen A3; non small cell lung cancer; TG1040; vaccine

Indexed keywords

CANCER VACCINE; CIMAVAX EGF; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; BONE PAIN; CANCER IMMUNIZATION; CANCER SURVIVAL; CHILL; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FEVER; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPHARMACOLOGY; INJECTION SITE PAIN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; NAUSEA; REVIEW; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; EPIDERMAL GROWTH FACTOR; HUMANS; LUNG NEOPLASMS;

EID: 84859788788     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.24     Document Type: Review

References (24)

1. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16), 3670-3679 (2009).
2. Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361(19), 1838-1847 (2009).
3. Salgaller ML: The development of immunotherapies for non-small cell lung cancer. Expert Opin. Biol. Ther. 2, 265-278 (2002). (Pubitemid 34464808)
4. Woo EY, Chu CS, Goletz TJ et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168, 4272-4276 (2002). (Pubitemid 34441324)
5. Nemunaitis J, Dillman RO, Schwarzenberger PO et al. Phase II study of belagenpumatucel-l, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24(29), 4721-4730 (2006). (Pubitemid 46630936)
6. Vansteenkiste J, Zielinski M, Linder A et al. Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J. Clin. Oncol. 25(18S), Abstract 7554 (2007).
7. Raina D, Kosugi M, Ahmad R et al. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol. Cancer Ther. 10(5), 806-816 (2011).
8. Butts C, Murray N, Maksymiuk A et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 23(27), 6674-6681 (2005). (Pubitemid 46190262)
9. Butts C, Maksymiuk A, Goss G et al. A multi-centre Phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of nonsmall cell lung cancer (NSCLC): Updated survival analysis: B1-01. J. Thor. Oncol. 2(8), S332-S333 (2007).
10. Butts C, Murray RN, Smith CJ et al. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small cell lung cancer. Clin. Lung Cancer 11(6), 391-395 (2010).
11. Ramlau R, Quoix E, Rolski J et al. A Phase II study of Tg4010 (Mva-Muc1-IL2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J. Thorac. Oncol. 3(7), 735-744 (2008).
12. Acres B, Quoix E, Ramlau R et al. Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010. J. Clin. Oncol. S27, 3027 (2009).
13. Rodriguez G, Albisa A, Viña L et al. Manufacturing process development for an epidermal growth factor-based cancer vaccine. Biopharm. Int. 21(10), 36-42 (2008).
14. Gonzalez G, Crombet T, Lage A. Chronic vaccination with a therapeutic EGF-based cancer vaccine: A review of patients receiving long lasting treatment. Curr. Cancer Drug Targets 11(1), 103-110 (2007).
15. Hoos A, Parmiani G, Hedge K et al. A Clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 30 (1), 1-15 (2007). (Pubitemid 46052199)
16. González G, Crombet T, Catalá M. et al. A novel cancer vaccine composed of human recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial. Ann. Oncol. 9(4), 431-435 (1998). (Pubitemid 28273037)
17. Gonzalez G, Crombet T, Torres F et al. Epidermal growth factor-based cancer vaccine for non-small cell lung cancer therapy. Ann. Oncol. 14 (3), 461-466 (2003). (Pubitemid 36367426)
18. Ramos TC, Vinageras EN, Ferrer MC et al. Treatment of NSCLC patients with an EGF-based cancer vaccine: Report of a Phase I trial. Cancer Biol. Ther. 5(2), 145-149 (2006). (Pubitemid 43327531)
19. González G, Crombet T, Neninger E et al. Therapeutic vaccination with epidermal growth factor/EGF) in advanced lung cancer: Analysis of pooled data from three clinical trials. Hum. Vaccin. 3(1), 8-13 (2007).
20. Neninger E, Verdecia BG, Crombet T et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced non small cell lung cancer. J. Immunother. 32(1), 92-99 (2009).
21. Neninger E, de la Torre A, Osorio M et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell-lung cancer. J. Clin. Oncol. 26 (9), 1452-1458 (2008).
22. García B, Neninger E, de la Torre A et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin. Cancer Res. 14(3), 840-846 (2008). (Pubitemid 351231168)
23. Rodriguez PC, Neninger E, García B et al. Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an epidermal growth factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients. J. Immune Based Ther. Vaccines 9, 7 (2011).
24. Gonzalez G, Crombet T, Lage A. Chronic vaccination with a therapeutic EGF-based cancer vaccine: A review of patients receiving long lasting treatment. Curr. Cancer Drug Targets 11(1), 103-110 (2011).